ChronTech develops drugs against chronic disease based on proprietary and other parties' patented and patent pending technologiesbla_glas_labb

 

ChronTech AB develops the therapeutic DNA-vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech.



CEO Statement

 

 

Latest Reports

2013-05-03
>> Interim Report January-March 2013
2013-01-25
>> Year-end Report 2012






Latest press releases

>> More press releases
>> Subscribe